PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20211007-5	2010	We therefore explored whether the known NFkappaB inhibitor celastrol could represent a suitable compound for decreasing Abeta production and accumulation in vivo.	celastrol	59-68	amyloid beta (A4) precursor protein	Mus musculus	120-125	
20211007-6	2010	METHODS: The effect of celastrol on amyloid precursor protein (APP) processing, Abeta production and NFkappaB activation was investigated by western blotting and ELISAs using a cell line overexpressing APP.	celastrol	23-32	amyloid beta (A4) precursor protein	Mus musculus	36-61	
20211007-13	2010	In addition, a reduction in Abeta plaque burden and microglial activation was observed in the brains of Tg PS1/APPsw following a chronic administration of celastrol.	celastrol	155-164	amyloid beta (A4) precursor protein	Mus musculus	28-33	
20211007-14	2010	CONCLUSIONS: Overall our data suggest that celastrol is a potent Abeta lowering compound that acts as an indirect BACE-1 inhibitor possibly by regulating BACE-1 expression level via an NFkappaB dependent mechanism.	celastrol	43-52	amyloid beta (A4) precursor protein	Mus musculus	65-70